Scancell Holdings plc (AIM:SCLP)
London
· Delayed Price · Currency is GBP · Price in GBX 12.95
+0.10 (0.78%)
Mar 6, 2026, 4:29 PM GMT
Scancell Holdings Revenue
Scancell Holdings had revenue of 4.71M GBP in the twelve months ending October 31, 2025. In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M.
Revenue
4.71M
Revenue Growth
n/a
P/S Ratio
28.31
Revenue / Employee
78.52K
Employees
60
Market Cap
133.35M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 4basebio | 1.78M |
| Bioventix | 13.12M |
| Avacta Group | 113.00K |
| PureTech Health | 4.66M |
| hVIVO | 54.47M |
| Ondine Biomedical | 1.18M |
| ImmuPharma | -69.96K |
| Arecor Therapeutics | 5.06M |
Scancell Holdings News
- 5 weeks ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire
- 6 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 8 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire
- 2 years ago - PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free - Business Wire